Royal Examiner notes eligibility hinges on BMI and certain conditions, and the program runs apart from Part D with its own coverage and payment rules.
Recap by typeshit. Post by Royal Examiner on X.
Hanmi set Eppe's first four weeks at 129,800 won ahead of a late-month launch, while Novo seeks Korean insurance coverage for Wegovy in high-risk patients.
Novo trades near 11.8 times forward earnings against an 18.6 average, and the piece asks whether that makes it a buying chance or a value trap.
About half of Australia's roughly 500,000 GLP-1 users pay privately, A$200 to $700 a month, and the authors argue cost hits those with the most obesity hardest.
Ireland's drug pricing body recommended semaglutide over tirzepatide for cost reasons, and Higgins says it's the right call, with a pun he didn't get to use.
Edinburgh researchers say no more than half the drop in heart disease traced back to known risk factors, and suggest treating semaglutide as a heart drug too.
Safety data on GLP-1 use in pregnant women with diabetes is still thin, so an expert panel put together consensus guidance on the key questions.
Loading…